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Psoriatic epidermis shows excessive cell proliferation, incomplete morphogenesis, and 
glycogen accumulation. These three features may result from coordinate misregulation by 
the previously reported abnormallesional ratio of cyclic AMP/cyclic GMP.If so, it is possible 
that psoriasis might improve by topical application of an agent known to alter cellular levels 
of cyclic nucleotides. In the present study papaverine (3.0 x to-' M) produced a 210% 
increase (.02 < p < .05) in epidermal cyclic AMP levels in vitro. Therefore, 1% papaverine 
cream (approximately 2.7 x 10- 2 M papaverine) was chosen to establish whether a cyclic 
AMP elevating agent could improve a psoriatic lesion. A double-blind comparison of 1% 
papaverine cream versus cream alone was conducted on matched lesions in 45 patients. Of 
those patients showing differential improvement (i.e., only one lesion of the pair improved), 
81% (p ~ 0.011) of those showing a response in the center of the lesion and 77% (p ~ 0.046) of 
those improving at the edge had applied papaverine. Although no attempts were made to 
develop a papaverine formulation with immediate therapeutic utility, the numerically 
significant papaverine results suggest future therapeutic developments. 
Rapid cell proliferation [I), incomplete mor-
phogenesis [2]. and glycogen accumulation (3) are 
characteristic of the epidermis in a steady-state 
psoriatic lesion. These abnormal characteristics 
may be the result of the previously detected 
abnormal ratio of cyclic adenosine 3' ,5' -monophos-
phate (cyclic AMP) to cyclic guanosine 3' ,5' -mono-
phosphate (cyclic GMP) in the lesion [4). In other 
systems these two cyclic nucleotides are intracellu-
lar modulators of many programmed cell functions 
[5,6). 
If this abnormal ratio in the lesion is indeed 
important in the pathogenesis of psoriasis, restora-
tion of coordinate regulation of epidermal pro-
grammed cell functions might be effected by 
changing this ratio with an agent known to alter 
cyclic nucleotide levels. 
The effects of papaverine on intraepidermal 
cyclic AMP levels were measured in vitro since this 
agent elevates cyclic AMP in other tissues by 
inhibiting cyclic AMP phosphodiesterase [7]. The 
same agent (papaverine) was then applied to 
psoriatic lesions in vivo to determine whether a 
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differential improvement could be detected in 
comparison with the control. This report demon-
strates that papaverine elevates cyclic AMP levels 
in mammalian epidermis in vitro. Moreover, topi-
cal papaverine produced a statistically significant 
improvement of psoriatic lesions. 
MATERIALS AND METHODS 
Hairless mouse (hr/hr) epidermis obtained by kerato-
tcming at a depth of 0.1 mm was sliced into 3- to 5-mm 
pieces. Epidermal purity was monitored histologically as 
previously described [8]. These pieces were incubated in 
Krebs-Ringer hicarbonate medium containing 0.5% glu-
cose at 37'C. Portions of epidermis from both the control 
vessel and that containing papaverine HCl (3.0 x 10-' M) 
were placed in liquid nitrogen after 5, 10, and 15 min of 
incubation. The extracted cyclic AMP was partially 
purified by anion exchange column chromatcgraphy as 
previously described [4] and assayed by the method of 
Gilman [9J. Epidermal DNA was determined by the 
method of Burton [10]. A test for statistical significance 
of accumulation of cyclic AMP in the presence of 
papaverine was performed by the one-tailed, Student's 
t-test for paired data [11 J. 
For clinical studies 1% papaverine HCl (Mallinckrodt 
Chemical Co., St. Louis, Mo.) cream was prepared by the 
University of Michigan Hospital Pharmacy. In order to 
determine the final concentration of papaverine HCI in 
the cream, the optical density reading at 250 nm, 
ohtained by extracting the cream with ether after treat-
ment with 0.05 N sulfuric acid, was compared to a 
standard curve of various concentrations of papaverine 
HCl in 0.05 N sulfuric acid. The cream contained: cetyl 
alcohol, stearyl alcohol, sodium lauryl sulfate, white 
petrolatum, propylene glycol, and distilled water. The 
pH of papaverine HCl cream was 6.1 whereas the pH of 
the cream base alone was 6.0. 
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The same cream without papaverine was used on 
control lesions. Pairs of jars, one containing papaverine 
cream and the other containing the cream alone as 
control, were labeled with code letters using a table of 
random numbers. Both creams had the same color. 
Neither investigators nor patients knew which jar con· 
tained papaverine until after the data had been analyzed. 
Sixty-nine outpatients with typical plaques of psoria-
sis were chosen for the study. Two lesions approximately 
5 em in diameter were selected on each patient. The 
previously coded jars were randomly assigned to the 2 
lesions. The patient was then instructed to apply only the 
contents of the appropriate jar to its assigned lesion. 
Patients applied the creams 4 times a day for 4 weeks 
under plastic occlusion. since a pilot study had shown no 
effect without occlusion. Between applications 1 to 2 hr of 
air drying were permitted such that the creams were 
occluded between 16 and 20 hr per day. Several patients 
with extensive psoriasis used topical steroids on areas 
distant to the 2 test lesions but no systemic medications 
for psoriasis were permitted. 
Each test lesion was evaluated independently by two 
physicians 2 and 4 weeks after the initiation of the study. 
Progress was judged not by loss of scale but by reduction 
in lesion thickness. Lesion improvement was scored as 
follows: 0 ~ none; 1 + ~ minimal; 2+ ~ moderate 
(decreased thickness and/or incomplete clearing); 3+ ~ 
complete clearing with or without residual redness or 
change in pigmentation. When scores disagreed, the 
lower score was used for statistical analysis. The edge and 
center of each lesion were scored separately since the edge 
is more mitotically active [12]. 
To monitor possible systemic toxicity due to percu-
taneous absorption of papaverine, the following serum 
parameters were determined in 21 patients during the 
4·week study: electrolytes, urea nitrogen, total bilirubin, 
glucose, total proteins. albumin, cholesterol, calcium, 
phosphorus, uric acid, creatinine, glutamic oxaloacetic 
transaminase, lactic dehydrogenase, and alkaline phos-
phatase. In addition. a white blood cell count, hematocrit, 
hemoglobin, red blood cell count. and urine analysis for 
sugar, ketones, and protein were obtained. 
For statistical analysis, a score of 0 or 1 + was 
designated unimproved and a score of 2+ or 3+ desig. 
nated improved at either 2 and/or 4 weeks of application. 
Those patients scored as "the same" on both lesions 
(both improved or both unimproved) were not statisti-
cally useful in evaluating differential improvement in 
response to papaverine or control cream. Clearly, only 
patients who had a lesion respond to papaverine while the 
matched lesion did not respond to control cream, or who 
had a lesion respond to control while the matched lesion 
did not respond to papaverine were meaningful in testing 
the possible differential improvement of papaverine ver-
Sus control. Using the data appropriate for differential 
improvement, a sign test [13] was used to test the 
hypothesis that papaverine yielded the same improve-
ment as control against the one-sided alternative that 
papaverine improved more lesions than control. 
RESULTS 
The Figure shows the cyclic AMP accumulation 
in mouse epidermis in vitro in the presence of 
papaverine (3.0 x 10-' M) as a function of time. 
The difference in the mean cyclic AMP levels in 
control and papaverine-treated epidermis was sig-
nificant at 15 min (.02 < p < .05) of incubation. 
Forty-five of 69 patients completed the clinical 
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experiment. Twenty-four patients were disquali-
fied for the following reasons: 4 failed to return; 5 
had total-body remission of psoriasis; 13 applied 
the creams less than our arbitrarily preagreed 
minimum of 37 (two-thirds) of the possible 56 
application times per 2-week period; and 2 began 
systemic anti psoriasis medications during the 4-
week study. 
The data obtained from the evaluation of those 
45 patients completing the study are summarized 
in the Table. With respect to the center of the 
lesions there were 16 patients who showed differen-
tial improvement-l3 had only the papaverine-
treated lesion improve and 3 had only the control 
cream-treated lesion improve. This 81% (13 out of 
16} improvement on papa\'erine is a statistically 
significant (p ~ 0_011) result. For the edge of the 
lesions, the corresponding values were: 1.3 patients 
showed differential improvement-1O for papaver-
ine-treated and 3 for control cream-treated le-
sions. This 77% (10 out of 13) improvement on 
papaverine is also statistically significant (p ~ 
0.046). None of the clinical laboratory studies 
revealed any abnormalities attributable to papav-
erine. 
DISCUSSION 
These results indicate that in patients for whom 
one lesion only improved, significantly more of 
these improved lesions had been treated with 
papaverine cream than had been treated with the 
control cream. The purpose of this study was to 
establish in principle whether an agent which is 
known to elevate cyclic AMP in epidermis in vitro 
could improve a psoriatic lesion in vivo. Psoriatic 
epidermis was not removed for biochemical analy-
sis of papaverine and cyclic AMP content before 
and after application of the creams since, if we had 
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FIG. Cyclic AMP accumulation in hairless mouse 
epidermis in response to papaverine. The percentages are 
the increases in cyclic AMP levels at each time point in 
papaverine (3.0 x 10-' M) -treated epidermis when com-
pared to control epidermis. The data are expressed as tbe 
mean (0 or.) ± 1 SEM (vertical lines) of 4 experiments. 
The difference in means at 15 min is statistically signifi-
cant (.02 < P < .05) using the Student's t-test for paired 
data. 
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TAllLE. Number of patients with psoriasis by type of 
response (improved or unimproved) to 1% papaverine 











* p ~ 0.011. 
t P ~ 0.046. 





















The sign test was applied to the two cells where 
differential improvement (improvement of only one le-
sion of a pair) was noted. For both center and edge there 
were statistically significantly more improved lesions 
treated with papaverine. 
clinical observation. Since the variability of cyclic 
AMP levels from lesion to lesion on the same 
patient is unknown, we elected not to compare the 
cyclic AMP levels in treated and untreated lesional 
epidermis. 
The 1% papaverine cream (approximately 2.7 x 
10- 2 M papaverine) was chosen somewhat arbitrar-
ily. It was known from the work of Prasad and 
Sheppard [141 that papaverine (1.3 x 10-' M) 
stimulates morphologic differentiation and inhib-
its cellular proliferation of cultured neuroblastoma 
cells presumably by elevating cellular levels of 
cyclic AMP. Therefore, for our in vitro measure-
ments we used a similar papaverine concentration 
(3.0 x 10-< M). Although this concentration ele-
vated epidermis cyclic AMP levels in vitro, we do 
not know whether 1% papaverine cream elevated 
psoriatic lesional cyclic AMP levels in vivo since 
the concentration reaching the cells is unknown. 
Although one can measure drug penetration across 
epidermis in vitro, it is very difficult to relate in 
vitro penetration data to in vivo percutaneous 
absorption from a cream. Since our pilot studv 
without occlusion suggested that papaverine hy-
drochloride might penetrate psoriatic epidermis 
poorly, occlusion was used. It is a long-standing 
clinical observation that water-tight occlusion en-
hances percutaneous absorption [15]_ However, 
occlusion may have lowered the sensitivity of our 
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experiment to detect differential improvement 
since occlusive plastic dressings are known to 
inhibit psoriatic epidermal proliferation [16], 
Nonetheless, the data indicate that occluded pa-
paverine cream was superior to occluded control 
cream. The difference in mitotic activitv in the 
center of the lesion versus that found in the edge 
[12] did not appear to appreciably alter the re-
sponse of the lesions to the cream, 
The sensitivity of cyclic AMP phosphodiesterase 
in the lesion to inhibition by papaverine is not 
known. In a preliminary study of 6 patients, the 
"low K .. " cyclic AMP phosphodiesterase of le-
sional epidermis has a threefold increase in V rna, in 
comparison with uninvolved epidermis as assayed 
in a 17,000 g supernatant and when subjected to 
Eadie-Hofstee and Lineweaver-Burk analyses [17 I. 
~ot all forms of cyclic phosphodiesterase are 
equally susceptible te inhibition by papaverine. It 
is possible that the lesional cyclic AMP phosphodi-
esterase is less susceptible to papaverine inhibition 
[181 than the phosphodiesterase of normal or 
uninvolved epidermis and could account for the 
lack of dramatic improvement in some of the 
papaverine-treated lesions, 
Moreover, we did not address ourselves to me-
dicinal chemical considerations which are fre-
quently critical to the formulation of an efficacious 
preparation. Based on our previous clinical exper-
ience, the papaverine preparation used in this 
study is unequivocally inferior to most concentra-
tions of topical glucocorticoids currently used in 
psoriasis therapy. In this regard 3 of 13 lesions 
treated with papaverine in the center and 4 of 10 at 
the edge had 3+ responses (cleared completely), 
whereas 10 and 6 at the center and edge, respec-
tively, had 2~ responses (definite but incomplete 
clearing). We do not know whether this inferior 
response in comparison with glucocorticoids is the 
result of an insufficient concentration of papaver-
ine in the cream, fail ure of papaverine to leave the 
cream, poor cutaneous absorption, a concomitant 
rise in cyclic guanosine 3',5'-monophosphate (cy-
clic GMP), or a combination of these factors. 
We believe, however, that some papaverine en-
tered lesional epidermis and it was responsible for 
the observed differential improvement by increas-
ing the cyclic AMP/cyclic GMP ratio. Since pa-
paverine can inhibit oxidative phosphorylation 
[19] and may interfere with cell metabolism in 
other unknown ways, papaverine may have im-
proved psoriasis independent of an alteration in 
the cyclic nucleotide ratio. Only when psoriasis is 
improved by several other hormones or agents 
known to raise cyclic AMP by different mech-
anisms, alone or in combination, can it be said that 
cyclic AMP elevation improves psoriasis, Since 
this study was completed, non-double-blind stud-
ies have been published showing some positive 
results using theophylline and dibutyryl cyclic 
AMP topically [20]. dibutyryl cyclic AMP intra-
muscularly [211. and 5'AMP intramuscularly [22] 
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for the treatment of psoriasis. These reports sug-
gest that this approach shows promise for future 
therapeutic considerations in psoriasis. 
We are indebted to Mr. Elvin G. Curtis. Assistant 
Director, Pharmacy Service, of tbe University of Michi· 
gan Hospital Pbarmacy for the manufacture of papaver· 
ine cream and for spectrophotometric measurement of its 
papaverine content. We acknowledge the excellent tech-
nicalassistance provided by Mr. David Chemin and Miss 
Noelle Acculto for assistance in the statistical evaluation. 
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